Allarity Therapeutics, Inc.
Allarity Therapeutics is a United States clinical-stage biopharmaceutical company developing targeted medicines for oncology. Its principal therapeutic development program includes a drug candidate aimed at PARP and WNT pathway activity, supported by approaches intended to predict which patients may respond to treatment. The company has also expanded commercial laboratory services, but its continuing investigational drug development distinguishes it from a pure diagnostics provider. Allarity trades on Nasdaq under ALLR. A dated 2026 SEC filing identifies its principal executive office in Tarpon Springs, Florida, superseding older website references to Boston.
Company at a glance
Corporate information
- Company entity
- Allarity Therapeutics, Inc.
- Headquarters / principal office
- United States
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://allarity.com/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Nasdaq: ALLR
PARP/WNT inhibition · drug response prediction
oncology
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Allarity Therapeutics is a United States clinical-stage biopharmaceutical company developing targeted medicines for oncology. Its principal therapeutic development program includes a drug candidate aimed at PARP and WNT pathway activity, supported by approaches intended to predict which patients may respond to treatment. The company has also expanded commercial laboratory services, but its continuing investigational drug development distinguishes it from a pure diagnostics provider. Allarity trades on Nasdaq under ALLR. A dated 2026 SEC filing identifies its principal executive office in Tarpon Springs, Florida, superseding older website references to Boston.
Business, technology & evidence
- SecuritiesNasdaq: ALLR
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Allarity Therapeutics, Inc. ↗Allarity Therapeutics, Inc. ·
- Official issuer and R&D disclosure · Allarity Therapeutics, Inc. ↗Allarity Therapeutics, Inc. ·
- Official issuer and R&D disclosure · Allarity Therapeutics, Inc. ↗Allarity Therapeutics, Inc. ·
- Official issuer and R&D disclosure · Allarity Therapeutics, Inc. ↗Allarity Therapeutics, Inc. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.